| Year |
Citation |
Score |
| 2021 |
Qiao J, Liang C, Zhao D, Nguyen LXT, Chen F, Suo S, Hoang DH, Pellicano F, Rodriguez IR, Elhajmoussa Y, Ghoda L, Yoshimura A, Stein AS, Ali H, Koller P, ... Perrotti D, et al. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia. PMID 34564700 DOI: 10.1038/s41375-021-01423-x |
0.383 |
|
| 2021 |
Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation. Molecular Cancer Therapeutics. PMID 33568357 DOI: 10.1158/1535-7163.MCT-20-0663 |
0.384 |
|
| 2020 |
Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld AK, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, ... ... Perrotti D, et al. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery. 1: 48-67. PMID 32974613 DOI: 10.1158/0008-5472.BCD-19-0039 |
0.388 |
|
| 2020 |
Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld A, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, ... ... Perrotti D, et al. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions Blood Cancer Discovery. 1: 48-67. DOI: 10.1158/0008-5472.bcd-19-0039 |
0.312 |
|
| 2019 |
Perrotti D, Agarwal A, Lucas CM, Narla G, Neviani P, Odero MD, Ruvolo PP, Verrills NM. Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia". Science Translational Medicine. 11. PMID 31316003 DOI: 10.1126/Scitranslmed.Aau0416 |
0.339 |
|
| 2019 |
Silvestri G, Trotta R, Stramucci L, Wang S, Eisfeld A, Zhang B, Srutova K, Pineda G, Jamieson C, Stagno F, Vigneri P, Nteliopoulos G, Guimond M, Hokland P, Deininger MW, ... ... Perrotti D, et al. A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity Blood. 134: 4141-4141. DOI: 10.1182/Blood-2019-131113 |
0.433 |
|
| 2019 |
Scarpa M, Singh P, Kapoor S, Lee JK, Niyongere S, Narla G, Perrotti D, Baer MR. PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation Blood. 134: 1276-1276. DOI: 10.1182/Blood-2019-129011 |
0.403 |
|
| 2018 |
Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. PMID 30049824 DOI: 10.3324/haematol.2018.193086 |
0.378 |
|
| 2018 |
Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, ... ... Perrotti D, et al. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nature Medicine. PMID 29505034 DOI: 10.1038/Nm.4499 |
0.352 |
|
| 2018 |
Scarpa M, Kapoor S, Perrotti D, Baer MR. Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc Blood. 132: 3951-3951. DOI: 10.1182/Blood-2018-99-117609 |
0.485 |
|
| 2017 |
Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR. Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29074603 DOI: 10.1158/1078-0432.CCR-17-1629 |
0.375 |
|
| 2016 |
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. Cancer Cell. 30: 349-351. PMID 27505674 DOI: 10.1016/J.Ccell.2016.07.007 |
0.302 |
|
| 2016 |
Laidlaw KM, Berhan S, Liu S, Silvestri G, Holyoake TL, Frank DA, Aggarwal B, Bonner MY, Perrotti D, Jørgensen HG, Arbiser JL. Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget. PMID 27438151 DOI: 10.18632/oncotarget.10541 |
0.453 |
|
| 2016 |
Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget. PMID 27374090 DOI: 10.18632/oncotarget.10209 |
0.379 |
|
| 2016 |
Perrotti D, Silvestri G, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in Chronic Myeloid Leukemia: the leukemic stem, progenitor and stromal cell interplay. Current Drug Targets. PMID 27307150 |
0.326 |
|
| 2016 |
Baldwin PR, Kapoor S, Natarajan K, Trotta R, Tron A, Huszar D, Davila E, Perrotti D, Baer MR. Concurrent Inhibition of Pim-1 and FLT3 Kinases in FLT3-ITD Acute Myeloid Leukemia Post-Translationally Downregulates the Anti-Apoptotic Protein Mcl-1 through Downregulation of the Mcl-1 Deubiquitinase USP9X Blood. 128: 35-35. DOI: 10.1182/BLOOD.V128.22.35.35 |
0.448 |
|
| 2016 |
Yu J, Silvestri G, Stramucci L, Sanada M, Yamaguchi T, Du Y, Westermarck J, Caligiuri MA, Garzon R, Milojkovic D, Apperley JF, Roy D, Marcucci G, Calabretta B, Baer MR, ... ... Perrotti D, et al. Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity Blood. 128: 2909-2909. DOI: 10.1182/Blood.V128.22.2909.2909 |
0.406 |
|
| 2016 |
Trotta R, Silvestri G, Stramucci L, Ellis JJ, Yu J, Harb JJ, Neviani P, Marcucci G, Srutova K, Machova PK, Roy D, Hokland P, Deininger M, Bhatia R, Gambacorti-Passerini C, ... ... Perrotti D, et al. Abstract 951: Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-β-catenin-modulator miR-300 in leukemic stem/progenitor proliferation and survival in CML Cancer Research. 76: 951-951. DOI: 10.1158/1538-7445.Am2016-951 |
0.371 |
|
| 2015 |
Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. PMID 25971362 DOI: 10.1038/leu.2015.106 |
0.314 |
|
| 2015 |
Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Molecular Cancer Research : McR. 13: 699-712. PMID 25828893 DOI: 10.1158/1541-7786.Mcr-14-0422 |
0.329 |
|
| 2015 |
Ciccone M, Calin GA, Perrotti D. From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Frontiers in Oncology. 5: 21. PMID 25763353 DOI: 10.3389/fonc.2015.00021 |
0.342 |
|
| 2015 |
Silvestri G, Stramucci L, Ellis J, Yu J, Harb J, Neviani P, Marcucci G, Srutova K, Machova Polakova K, Roy D, Hokland P, Deininger MW, Bhatia R, Gambacorti-Passerini C, Milojkovic D, ... ... Perrotti D, et al. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML Blood. 126: 53-53. DOI: 10.1182/Blood.V126.23.53.53 |
0.489 |
|
| 2015 |
Zhang B, Li L, Chen C, Stein AS, Ali H, Snyder DS, Lin A, Dorrance A, Swiderski P, Bhatia R, Perrotti D, Forman SJ, Kuo Y, Kortylewski M, Marcucci G. Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells Blood. 126: 51-51. DOI: 10.1182/Blood.V126.23.51.51 |
0.383 |
|
| 2015 |
Srutova K, Curik N, Jitka K, Savvulidi F, Klamova H, Perrotti D, Stopka T, Machova Polakova K. Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment Blood. 126: 1243-1243. DOI: 10.1182/BLOOD.V126.23.1243.1243 |
0.373 |
|
| 2014 |
Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Science Signaling. 7: ra36. PMID 24736457 DOI: 10.1126/Scisignal.2004762 |
0.392 |
|
| 2014 |
Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, Forman S, Perrotti D, Jove R, Bhatia R. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood. 123: 2826-37. PMID 24668492 DOI: 10.1182/blood-2013-05-505735 |
0.365 |
|
| 2014 |
Neviani P, Perrotti D. SETting OP449 into the PP2A-activating drug family. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2026-8. PMID 24634375 DOI: 10.1158/1078-0432.Ccr-14-0166 |
0.446 |
|
| 2014 |
Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, ... ... Perrotti D, et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. The Journal of Clinical Investigation. 124: 1512-24. PMID 24590286 DOI: 10.1172/Jci70921 |
0.466 |
|
| 2014 |
Silvestri G, Ellis J, Stramucci L, Harb JG, Neviani P, Marcucci G, Roy D, Hokland P, Milojkovic D, Reid A, Apperley JF, Livak FM, Baer MR, Trotta R, Perrotti D. MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay Blood. 124: 4529-4529. DOI: 10.1182/Blood.V124.21.4529.4529 |
0.443 |
|
| 2014 |
Natarajan K, Mathias TJ, Doshi KA, Tron AE, Kraus M, Trotta R, Perrotti D, Huszar D, Baer MR. The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation of Mcl-1 and of Bcl-xL Blood. 124: 3601-3601. DOI: 10.1182/Blood.V124.21.3601.3601 |
0.501 |
|
| 2013 |
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Perrotti D, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951 |
0.831 |
|
| 2013 |
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, ... ... Perrotti D, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 122: 3034-44. PMID 23970380 DOI: 10.1182/Blood-2013-04-495374 |
0.796 |
|
| 2013 |
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, ... ... Perrotti D, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122: 1923-34. PMID 23926298 DOI: 10.1182/Blood-2013-03-492181 |
0.795 |
|
| 2013 |
Balkhi MY, Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Science Signaling. 6: ra63. PMID 23901138 DOI: 10.1126/Scisignal.2004177 |
0.41 |
|
| 2013 |
Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia. 27: 1996-2005. PMID 23670294 DOI: 10.1038/Leu.2013.151 |
0.779 |
|
| 2013 |
Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. The Lancet. Oncology. 14: e229-38. PMID 23639323 DOI: 10.1016/S1470-2045(12)70558-2 |
0.475 |
|
| 2013 |
Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, Cheung DG, Bolon B, Anderlucci L, Alder H, Nuovo G, Li M, Iorio MV, Galasso M, Santhanam R, ... ... Perrotti D, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. Plos Genetics. 9: e1003311. PMID 23505378 DOI: 10.1371/Journal.Pgen.1003311 |
0.375 |
|
| 2013 |
Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of Hematology & Oncology. 6: 21. PMID 23497456 DOI: 10.1186/1756-8722-6-21 |
0.772 |
|
| 2013 |
Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2355-67. PMID 23493348 DOI: 10.1158/1078-0432.Ccr-12-3191 |
0.369 |
|
| 2013 |
Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, ... ... Perrotti D, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. Embo Molecular Medicine. 5: 105-21. PMID 23180565 DOI: 10.1002/Emmm.201201283 |
0.74 |
|
| 2013 |
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 27: 871-8. PMID 23178755 DOI: 10.1038/Leu.2012.342 |
0.423 |
|
| 2013 |
Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leukemia & Lymphoma. 54: 1151-8. PMID 23121619 DOI: 10.3109/10428194.2012.745524 |
0.36 |
|
| 2013 |
Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, ... Perrotti D, et al. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 121: 159-69. PMID 23100311 DOI: 10.1182/Blood-2012-05-428573 |
0.706 |
|
| 2013 |
Harb J, Neviani P, Ellis JE, Ferenchak GJ, Chyla BI, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti D. Abstract 3454: Bcl-xL anti-apoptotic network is dispensable for emergence and maintenance of CML but required for disease progression, and represents an alternative target for halting survival of blast crisis CML progenitors. Cancer Research. 73: 3454-3454. DOI: 10.1158/1538-7445.Am2013-3454 |
0.328 |
|
| 2013 |
Tarighat SS, Mahasenan K, Perrotti D, Garzon R, Caligiuri M, Li C, Blum W, Marcucci G, Baiocchi RA. Abstract 1128: Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia . Cancer Research. 73: 1128-1128. DOI: 10.1158/1538-7445.Am2013-1128 |
0.505 |
|
| 2013 |
Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC. Erratum: miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR (Science Signaling (2013) 6 (er6)) Science Signaling. 6. DOI: 10.1126/Scisignal.292Er6 |
0.357 |
|
| 2012 |
Perrotti D. Where are we going with CML research? Leukemia Supplements. 1: S51-3. PMID 27175251 DOI: 10.1038/leusup.2012.26 |
0.32 |
|
| 2012 |
Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G, Garzon R, Croce CM. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America. 109: 20047-52. PMID 23169640 DOI: 10.1073/Pnas.1213764109 |
0.427 |
|
| 2012 |
Perrotti D, Neviani P. Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia. Cell Cycle (Georgetown, Tex.). 11: 4300-1. PMID 23159861 DOI: 10.4161/Cc.22808 |
0.513 |
|
| 2012 |
Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, ... ... Perrotti D, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 22: 645-55. PMID 23153537 DOI: 10.1016/J.Ccr.2012.09.009 |
0.34 |
|
| 2012 |
Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, ... ... Perrotti D, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proceedings of the National Academy of Sciences of the United States of America. 109: E2110-6. PMID 22753494 DOI: 10.1073/Pnas.1209414109 |
0.348 |
|
| 2012 |
Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, ... ... Perrotti D, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 119: 6025-31. PMID 22566605 DOI: 10.1182/Blood-2012-03-413898 |
0.449 |
|
| 2012 |
Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, ... ... Perrotti D, et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood. 119: 4786-97. PMID 22408260 DOI: 10.1182/Blood-2011-10-387522 |
0.398 |
|
| 2012 |
Alachkar H, Maharry K, Santhanam R, Neviani P, Volinia S, Kohlschmidt J, Metzeler KH, Dorrance AM, Schwind S, Becker H, Mendler JH, Eisfeld A, Whitman S, Mrózek K, Garzon R, ... Perrotti D, et al. SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML) Blood. 120: 773-773. DOI: 10.1182/Blood.V120.21.773.773 |
0.475 |
|
| 2012 |
Magistroni V, Sharma N, Piazza R, Harb JG, Spinelli R, Pirola A, Ellis J, Dong-Wook K, Perrotti D, Gambacorti-Passerini C. Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia Blood. 120: 3727-3727. DOI: 10.1182/Blood.V120.21.3727.3727 |
0.407 |
|
| 2012 |
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis J, Marcucci G, Landesman Y, Shacham S, Kauffman M, Perrotti D. Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL Blood. 120: 35-35. DOI: 10.1182/Blood.V120.21.35.35 |
0.813 |
|
| 2012 |
Huang X, Schwind S, Eisfeld A, Yu B, Santhanam R, Hoellerbauer P, Jin Y, Hickey C, Pang J, Chan KK, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield CD, et al. Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). Blood. 120: 2422-2422. DOI: 10.1182/Blood.V120.21.2422.2422 |
0.437 |
|
| 2012 |
Schwind S, Blum W, Liu S, Tarighat SS, Geyer S, Klisovic R, Eisfeld A, Walker A, Whitman S, Ramasamy S, Wu Y, Jacob S, Caligiuri M, Grever M, Perrotti D, et al. Abstract CT-06: The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Ct-06 |
0.484 |
|
| 2012 |
Walker C, Oaks JJ, Santhanam R, Neviani P, Harb JG, Paisie C, Marcucci G, Landesman Y, Shacham S, Kauffman M, Perrotti D. Abstract 3839: Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias Cancer Research. 72: 3839-3839. DOI: 10.1158/1538-7445.Am2012-3839 |
0.808 |
|
| 2012 |
Mims AS, Walker AR, Hoellerbauer P, Huang X, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen C, Blum W, Garzon R, Schwind S, Marcucci G. Abstract 119: AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML) Cancer Research. 72: 119-119. DOI: 10.1158/1538-7445.Am2012-119 |
0.446 |
|
| 2012 |
Huang X, Sebastian S, Eisfeld A, Jin Y, Yu B, Hickey C, Pang J, Ramasamy S, Chan K, Perrotti D, Muthusamy N, Byrd J, Blum W, Bloomfield C, Liu S, et al. Abstract 1111: SyntheticmicroRNA (miR)-181ananoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML) Cancer Research. 72: 1111-1111. DOI: 10.1158/1538-7445.Am2012-1111 |
0.439 |
|
| 2011 |
Simon GR, Saddoughi S, Mukhopadhyay A, Peterson Y, Senkal CE, Oaks J, Perrotti D, Hannun Y, Ogretmen B. Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7574. PMID 28023125 DOI: 10.1200/Jco.2011.29.15_Suppl.7574 |
0.749 |
|
| 2011 |
Carella AM, Goldman JM, Martinelli G, Melo JV, Perrotti D. Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica. 96: 1737-9. PMID 22147770 DOI: 10.3324/Haematol.2011.052571 |
0.389 |
|
| 2011 |
Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, ... ... Perrotti D, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 117: 5941-52. PMID 21527515 DOI: 10.1182/Blood-2010-08-300772 |
0.76 |
|
| 2011 |
Veronese A, Visone R, Consiglio J, Acunzo M, Lupini L, Kim T, Ferracin M, Lovat F, Miotto E, Balatti V, D'Abundo L, Gramantieri L, Bolondi L, Pekarsky Y, Perrotti D, et al. Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proceedings of the National Academy of Sciences of the United States of America. 108: 4840-5. PMID 21383185 DOI: 10.1073/Pnas.1101734108 |
0.375 |
|
| 2011 |
Perrotti D, Harb JG. BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention. Leukemia & Lymphoma. 52: 30-44. PMID 21299458 DOI: 10.3109/10428194.2010.546914 |
0.479 |
|
| 2011 |
Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP, Goldman J. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 96: 590-601. PMID 21242185 DOI: 10.3324/Haematol.2010.035675 |
0.424 |
|
| 2011 |
Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, Yu J, Zhang J, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood. 117: 2378-84. PMID 21156847 DOI: 10.1182/Blood-2010-05-285130 |
0.448 |
|
| 2011 |
Walker AR, Metzeler KH, Geyer S, Becker H, Schwind S, Whitman SP, Curfman J, Wu Y, Perrotti D, Klisovic RB, Garzon R, Blum W, Marcucci G. Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML) Blood. 118: 944-944. DOI: 10.1182/Blood.V118.21.944.944 |
0.323 |
|
| 2011 |
Huang X, Schwind S, Yu B, Pang J, Santhanam R, Chan KK, Garzon R, Blum W, Bloomfield CD, Liu S, Perrotti D, Lee RJ, Byrd JC, Muthusamy N, Lee LJ, et al. Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML) Blood. 118: 81-81. DOI: 10.1182/Blood.V118.21.81.81 |
0.413 |
|
| 2011 |
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Paisie C, Marcucci G, Shacham S, Kauffman M, Perrotti D. Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity, Blood. 118: 3758-3758. DOI: 10.1182/Blood.V118.21.3758.3758 |
0.82 |
|
| 2011 |
Harb JG, Neviani P, Huettner CS, Marcucci G, Perrotti D. Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1+in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34+/CD38− Stem and CD34+ progenitor Cells From CML-BC Patients Blood. 118: 2738-2738. DOI: 10.1182/Blood.V118.21.2738.2738 |
0.549 |
|
| 2011 |
Alachkar H, Santhanam R, Lucas DM, Schwind S, Hickey C, Pang J, Perrotti D, Pan L, Kinghorn AD, Marcucci G, Grever MR. Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML) Blood. 118: 2616-2616. DOI: 10.1182/Blood.V118.21.2616.2616 |
0.523 |
|
| 2011 |
Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Neviani P, Harb JG, Ogretmen B, Bittman R, Levine RL, Quintás-Cardama A, Marcucci G, Perrotti D. FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration Blood. 118: 2494-2494. DOI: 10.1182/Blood.V118.21.2494.2494 |
0.804 |
|
| 2011 |
Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, ... ... Perrotti D, et al. Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-109 |
0.831 |
|
| 2011 |
Liu Z, Wang H, Wu L, Xie Z, Du L, Mo X, Chiu M, Perrotti D, Grever M, Byrd JC, Liu S, Marcucci G, Chan KK. Abstract 2014: Modulation of DNA methyltransferases in leukemia cells by curcumin and its associated anti-leukemia activities Cancer Research. 71: 2014-2014. DOI: 10.1158/1538-7445.Am2011-2014 |
0.461 |
|
| 2010 |
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 18: 367-81. PMID 20951946 DOI: 10.1016/J.Ccr.2010.09.005 |
0.439 |
|
| 2010 |
Perrotti D, Eiring AM. The new role of microRNAs in cancer. Future Oncology (London, England). 6: 1203-6. PMID 20799864 DOI: 10.2217/Fon.10.78 |
0.593 |
|
| 2010 |
Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 18: 74-87. PMID 20609354 DOI: 10.1016/J.Ccr.2010.04.025 |
0.471 |
|
| 2010 |
Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. The Journal of Clinical Investigation. 120: 2254-64. PMID 20592475 DOI: 10.1172/Jci41246 |
0.407 |
|
| 2010 |
Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Research. 70: 5438-47. PMID 20551067 DOI: 10.1158/0008-5472.Can-09-2544 |
0.476 |
|
| 2010 |
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, ... ... Perrotti D, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 17: 333-47. PMID 20385359 DOI: 10.1016/J.Ccr.2010.03.008 |
0.682 |
|
| 2010 |
Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, ... ... Perrotti D, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 140: 652-65. PMID 20211135 DOI: 10.1016/J.Cell.2010.01.007 |
0.805 |
|
| 2010 |
Oaks JJ, Mukhopadhyay A, Santhanam R, Saddoughi SA, Walker C, Neviani P, Harb JG, Ma Y, Verstovsek S, Marcucci G, Briesewitz R, Bittman R, Chen C, Quintas-Cardama A, Ogretmen B, ... Perrotti D, et al. Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders Blood. 116: 775-775. DOI: 10.1182/Blood.V116.21.775.775 |
0.803 |
|
| 2010 |
Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, ... ... Perrotti D, et al. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment Blood. 116: 515-515. DOI: 10.1182/Blood.V116.21.515.515 |
0.83 |
|
| 2010 |
Walker C, Oaks JJ, Neviani P, Harb JG, Santhanam R, Ma Y, Marcucci G, Van Brocklyn J, Chen C, Bittman R, Perrotti D. PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives Blood. 116: 2901-2901. DOI: 10.1182/Blood.V116.21.2901.2901 |
0.801 |
|
| 2010 |
Zorko N, Whitman SP, Bernot K, Ngangana MT, Siebenaler R, Liu S, Wu Y, Kalu C, Zhang X, Jarjoura D, Xie Z, Chan KK, Dorrance AM, Lee BH, Briesewitz R, ... Perrotti D, et al. The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia Blood. 116: 150-150. DOI: 10.1182/Blood.V116.21.150.150 |
0.439 |
|
| 2010 |
Harb JG, Neviani P, Oaks JJ, Marcucci G, Hokland P, Roy D, Perrotti D. The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML. Blood. 116: 1222-1222. DOI: 10.1182/Blood.V116.21.1222.1222 |
0.762 |
|
| 2010 |
Alachkar H, Liu S, Schwind S, Becker H, Metzeler KH, Hickey C, Pang J, Whitman SP, Chan KK, Garzon R, Lucas DM, Perrotti D, Wu L, Grever MR, Kinghorn AD, et al. Abstract 3558: The natural product silvestrol decreases oncogenic FLT3 andmiR-155levels inFLT3-ITD positive Acute Myeloid Leukemia (AML) cells Cancer Research. 70: 3558-3558. DOI: 10.1158/1538-7445.Am10-3558 |
0.451 |
|
| 2010 |
Eiring AM, Harb J, Neviani P, Oaks JJ, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, ... ... Perrotti D, et al. Abstract 1950: Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors Cancer Research. 70: 1950-1950. DOI: 10.1158/1538-7445.Am10-1950 |
0.803 |
|
| 2009 |
Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM. Chronic myeloproliferative diseases with and without the Ph chromosome: Some unresolved issues Leukemia. 23: 1708-1715. PMID 19641523 DOI: 10.1038/Leu.2009.142 |
0.388 |
|
| 2009 |
Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 114: 1374-82. PMID 19520806 DOI: 10.1182/Blood-2009-05-220814 |
0.431 |
|
| 2009 |
Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients Oncogene. 28: 1669-1681. PMID 19234487 DOI: 10.1038/Onc.2009.7 |
0.525 |
|
| 2009 |
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 113: 6411-8. PMID 19211935 DOI: 10.1182/Blood-2008-07-170589 |
0.394 |
|
| 2009 |
Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, Aimiuwu J, Pang J, Bhasin D, Neviani P, Fuchs JR, Plass C, Li PK, Li C, Huang TH, ... ... Perrotti D, et al. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. The Journal of Pharmacology and Experimental Therapeutics. 329: 505-14. PMID 19201992 DOI: 10.1124/Jpet.108.147934 |
0.344 |
|
| 2009 |
Benson DM, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 113: 2706-14. PMID 19060242 DOI: 10.1182/Blood-2008-05-159285 |
0.405 |
|
| 2009 |
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu Y, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, ... ... Perrotti D, et al. Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications. Blood. 114: 938-938. DOI: 10.1182/Blood.V114.22.938.938 |
0.503 |
|
| 2009 |
Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, ... ... Perrotti D, et al. Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors. Blood. 114: 855-855. DOI: 10.1182/Blood.V114.22.855.855 |
0.799 |
|
| 2009 |
Hickey C, Schwind S, Becker H, Alachkar H, Garzon R, Wu Y, Liu S, Perrotti D, Marcucci G. MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells. Blood. 114: 766-766. DOI: 10.1182/Blood.V114.22.766.766 |
0.425 |
|
| 2009 |
Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Ma Y, Mao C, Marcucci G, Chen C, Cortes J, Caligiuri MA, Hokland P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, ... ... Perrotti D, et al. FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor. Blood. 114: 3259-3259. DOI: 10.1182/Blood.V114.22.3259.3259 |
0.805 |
|
| 2009 |
Harb J, Neviani P, Huettner C, Marcucci G, Perrotti D. BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells. Blood. 114: 191-191. DOI: 10.1182/Blood.V114.22.191.191 |
0.528 |
|
| 2008 |
Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. Journal of Immunology (Baltimore, Md. : 1950). 181: 3784-92. PMID 18768831 DOI: 10.4049/Jimmunol.181.6.3784 |
0.378 |
|
| 2008 |
Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Reviews. 27: 159-68. PMID 18213449 DOI: 10.1007/S10555-008-9119-X |
0.489 |
|
| 2008 |
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, ... Perrotti D, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 111: 2364-73. PMID 18083845 DOI: 10.1182/Blood-2007-08-110171 |
0.351 |
|
| 2008 |
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood. 111: 816-28. PMID 17925491 DOI: 10.1182/Blood-2007-05-090472 |
0.828 |
|
| 2008 |
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 111: 275-84. PMID 17761520 DOI: 10.1182/Blood-2006-10-053884 |
0.475 |
|
| 2008 |
Neviani P, Santhanam R, Ma Y, Marcucci G, Byrd JC, Chen C, Cortes J, Caligiuri MA, Huettner C, Bhatia R, Roy D, Perrotti D. Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38− Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals Blood. 112: 189-189. DOI: 10.1182/Blood.V112.11.189.189 |
0.428 |
|
| 2007 |
Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Setchell KD, Zheng Y, Harris CE, Williams DA. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 12: 467-78. PMID 17996650 DOI: 10.1016/J.Ccr.2007.10.015 |
0.418 |
|
| 2007 |
Trotta R, Ciarlariello D, Dal Col J, Allard J, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. The Journal of Experimental Medicine. 204: 2397-405. PMID 17875674 DOI: 10.1084/Jem.20070419 |
0.396 |
|
| 2007 |
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, ... ... Perrotti D, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095 |
0.819 |
|
| 2007 |
Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, ... ... Perrotti D, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 110: 3695-705. PMID 17671235 DOI: 10.1182/Blood-2006-11-058941 |
0.46 |
|
| 2007 |
Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, ... ... Perrotti D, et al. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood. 110: 2600-9. PMID 17537995 DOI: 10.1182/Blood-2006-01-028647 |
0.462 |
|
| 2007 |
Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, Marburger TB, Wen J, Perrotti D, Bloomfield CD, Whitman SP. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood. 110: 1022-4. PMID 17475912 DOI: 10.1182/Blood-2006-12-061176 |
0.352 |
|
| 2007 |
Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 110: 994-1003. PMID 17475908 DOI: 10.1182/Blood-2007-03-078303 |
0.747 |
|
| 2007 |
Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. The Journal of Pharmacology and Experimental Therapeutics. 321: 953-60. PMID 17389244 DOI: 10.1124/Jpet.106.118406 |
0.413 |
|
| 2007 |
Perrotti D, Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1638-42. PMID 17363515 DOI: 10.1158/1078-0432.Ccr-06-2320 |
0.429 |
|
| 2007 |
Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, et al. Precancerous stem cells have the potential for both benign and malignant differentiation. Plos One. 2: e293. PMID 17356702 DOI: 10.1371/Journal.Pone.0000293 |
0.357 |
|
| 2007 |
Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells. Blood. 109: 2481-7. PMID 17110450 DOI: 10.1182/Blood-2006-10-050096 |
0.358 |
|
| 2007 |
Thomas EK, Cancelas JA, Chae H, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Zheng Y, Harris CE, Williams DA. Rac GTPases Are Potential Therapeutic Targets in p210-BCR-ABL-Induced Myeloproliferative Disease (MPD). Blood. 110: 465-465. DOI: 10.1182/Blood.V110.11.465.465 |
0.51 |
|
| 2007 |
Oaks JJ, Santhanam R, Briesewitz R, Perrotti D. Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders. Blood. 110: 3548-3548. DOI: 10.1182/Blood.V110.11.3548.3548 |
0.79 |
|
| 2007 |
Samanta AK, Chakravorty S, Wang Y, Cortes J, Kantarjian H, Champlin RE, Perrotti D, Arlinghaus RB. Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells. Blood. 110: 3342-3342. DOI: 10.1182/Blood.V110.11.3342.3342 |
0.549 |
|
| 2007 |
Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. Blood. 110: 33-33. DOI: 10.1182/Blood.V110.11.33.33 |
0.84 |
|
| 2007 |
Eiring AM, Neviani P, Calin GA, Roy DC, Croce CM, Perrotti D. MicroRNAs Act as Decoy Molecules To Restore Granulocytic Maturation of Differentiation-Arrested BCR/ABL+ Myeloid Precursors. Blood. 110: 31-31. DOI: 10.1182/Blood.V110.11.31.31 |
0.688 |
|
| 2006 |
Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. British Journal of Cancer. 95: 775-81. PMID 16953242 DOI: 10.1038/Sj.Bjc.6603317 |
0.508 |
|
| 2006 |
Lee YJ, Jones LC, Timchenko NA, Perrotti D, Tenen DG, Kogan SC. CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities. Blood. 108: 2416-9. PMID 16788101 DOI: 10.1182/Blood-2006-02-003582 |
0.36 |
|
| 2006 |
Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. Journal of Controlled Release : Official Journal of the Controlled Release Society. 112: 199-207. PMID 16564596 DOI: 10.1016/J.Jconrel.2006.02.011 |
0.31 |
|
| 2006 |
Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, Zhang Y, Martinez R, Perrotti D, Calabretta B. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood. 107: 4080-9. PMID 16418324 DOI: 10.1182/Blood-2005-08-3181 |
0.529 |
|
| 2006 |
Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 107: 2507-16. PMID 16293596 DOI: 10.1182/Blood-2005-09-3732 |
0.519 |
|
| 2006 |
Trotta R, Col JD, Allard J, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Modi A, Blaser BW, Perrotti D, Caligiuri MA. In Vitro and In Vivo Evidence That the PP2A Inhibitor SET Regulates IFN-γ Production in Monokine-Stimulated Natural Killer Cells. Blood. 108: 928-928. DOI: 10.1182/Blood.V108.11.928.928 |
0.342 |
|
| 2006 |
Liu S, Pang J, Yu J, Liu Z, Huynh L, Kearney J, Paschka P, Klisovic RB, Baiocchi R, Blum W, Perrotti D, Marcucci G. Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF-kB in AML1/ETO-Positive Cells. Blood. 108: 4211-4211. DOI: 10.1182/Blood.V108.11.4211.4211 |
0.535 |
|
| 2006 |
Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy D, Caligiuri MA, Bloomfield CD, Chen C, ... ... Perrotti D, et al. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. Blood. 108: 288-288. DOI: 10.1182/Blood.V108.11.288.288 |
0.831 |
|
| 2006 |
Chang J, Santhanam R, Briercheck E, Eiring A, Trotta R, Notari M, Roy D, Caligiuri MA, Perrotti D. Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL+ Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2. Blood. 108: 2240-2240. DOI: 10.1182/Blood.V108.11.2240.2240 |
0.739 |
|
| 2006 |
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Perrotti D, Chen C, Dalton JT, Byrd JC, Muthusamy N. FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma. Blood. 108: 2095-2095. DOI: 10.1182/Blood.V108.11.2095.2095 |
0.472 |
|
| 2006 |
Sun J, Liu S, Yu J, Wei M, Mao C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic RB, Perrotti D, Chen C, Blum WG, Marcucci G. Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines. Blood. 108: 1988-1988. DOI: 10.1182/Blood.V108.11.1988.1988 |
0.426 |
|
| 2005 |
Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, ... ... Perrotti D, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 8: 355-68. PMID 16286244 DOI: 10.1016/J.Ccr.2005.10.015 |
0.553 |
|
| 2005 |
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9234-42. PMID 16275934 DOI: 10.1200/Jco.2005.03.6137 |
0.389 |
|
| 2005 |
Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, Yu J, Becknell B, Li Y, Liu C, Vukosavljevic T, Whitman SP, Chang KS, Byrd JC, Perrotti D, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Research. 65: 1277-84. PMID 15735013 DOI: 10.1158/0008-5472.Can-04-4532 |
0.359 |
|
| 2005 |
Chang J, Notari M, Marcucci G, Perrotti D. BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases. Blood. 106: 4376-4376. DOI: 10.1182/Blood.V106.11.4376.4376 |
0.494 |
|
| 2005 |
Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Chang J, Liu S, Mao H, Oaks JJ, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, ... Perrotti D, et al. ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. Blood. 106: 1992-1992. DOI: 10.1182/Blood.V106.11.1992.1992 |
0.807 |
|
| 2004 |
Perrotti D, Calabretta B. Translational regulation by the p210 BCR/ABL oncoprotein. Oncogene. 23: 3222-9. PMID 15094772 DOI: 10.1038/Sj.Onc.1207543 |
0.411 |
|
| 2004 |
Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 103: 4010-22. PMID 14982876 DOI: 10.1182/Blood-2003-12-4111 |
0.44 |
|
| 2004 |
Perrotti D, Marcucci G, Caligiuri MA. Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 582-4. PMID 14726508 DOI: 10.1200/Jco.2004.12.965 |
0.402 |
|
| 2004 |
Liu S, Klisovic MI, Shen T, Yu J, Dai G, Huynh L, Vukosavljevic T, Whitman S, Perrotti D, Marcucci G. Promotes Gene Expression by Disrupting the DNA Binding of the AML1/ETO and HDAC1 Repressor Complex. Blood. 104: 4386-4386. DOI: 10.1182/Blood.V104.11.4386.4386 |
0.406 |
|
| 2003 |
Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood. 102: 1267-75. PMID 12702500 DOI: 10.1182/Blood-2003-02-0477 |
0.396 |
|
| 2003 |
Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP, Caligiuri MA, Maraia RJ, Perrotti D, Calabretta B. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 3: 145-60. PMID 12620409 DOI: 10.1016/S1535-6108(03)00020-5 |
0.478 |
|
| 2002 |
Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene. 21: 8577-83. PMID 12476304 DOI: 10.1038/Sj.Onc.1206085 |
0.404 |
|
| 2002 |
Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, Bergamaschi A, Gambacorti-Passerini C, Calabretta B, Perrotti D. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Molecular and Cellular Biology. 22: 2255-66. PMID 11884611 DOI: 10.1128/Mcb.22.7.2255-2266.2002 |
0.493 |
|
| 2002 |
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nature Genetics. 30: 48-58. PMID 11753385 DOI: 10.1038/Ng791 |
0.449 |
|
| 2000 |
Perrotti D, Iervolino A, Cesi V, Cirinná M, Lombardini S, Grassilli E, Bonatti S, Claudio PP, Calabretta B. BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway. Molecular and Cellular Biology. 20: 6159-69. PMID 10913197 DOI: 10.1128/Mcb.20.16.6159-6169.2000 |
0.532 |
|
| 2000 |
Venturelli D, Cesi V, Ransac S, Engelhard A, Perrotti D, Calabretta B. The nucleoside diphosphate kinase activity of DRnm23 is not required for inhibition of differentiation and induction of apoptosis in 32Dcl3 myeloid precursor cells. Experimental Cell Research. 257: 265-71. PMID 10837140 DOI: 10.1006/Excr.2000.4899 |
0.399 |
|
| 2000 |
Manzella L, Gualdi R, Perrotti D, Nicolaides NC, Girlando G, Giuffrida MA, Messina A, Calabretta B. The interferon regulatory factors 1 and 2 bind to a segment of the human c-myb first intron: Possible role in the regulation of c-myb expression Experimental Cell Research. 256: 248-256. PMID 10739671 DOI: 10.1006/Excr.1999.4794 |
0.371 |
|
| 2000 |
Cirinnà M, Trotta R, Salomoni P, Kossev P, Wasik M, Perrotti D, Calabretta B. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation Blood. 96: 3915-3921. DOI: 10.1182/Blood.V96.12.3915.H8003915_3915_3921 |
0.465 |
|
| 1999 |
Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 96: 3092-7. PMID 10077642 DOI: 10.1073/Pnas.96.6.3092 |
0.398 |
|
| 1998 |
Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, Grassilli E, Lozzo RV, Cooper DR, Calabretta B. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. The Embo Journal. 17: 4442-55. PMID 9687511 DOI: 10.1093/Emboj/17.15.4442 |
0.494 |
|
| 1997 |
Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway Embo Journal. 16: 6151-6161. PMID 9321394 DOI: 10.1093/Emboj/16.20.6151 |
0.495 |
|
| 1997 |
Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B. Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo. Proceedings of the National Academy of Sciences of the United States of America. 94: 3966-71. PMID 9108088 DOI: 10.1073/Pnas.94.8.3966 |
0.365 |
|
| 1997 |
Salomoni P, Perrotti D, Martinez R, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Proceedings of the National Academy of Sciences of the United States of America. 94: 3296-301. PMID 9096387 DOI: 10.1073/Pnas.94.7.3296 |
0.403 |
|
| 1997 |
Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. Journal of the National Cancer Institute. 89: 124-33. PMID 8998181 DOI: 10.1093/Jnci/89.2.124 |
0.438 |
|
| 1997 |
Bellon T, Perrotti D, Calabretta B. Granulocytic Differentiation of Normal Hematopoietic Precursor Cells Induced by Transcription Factor PU.1 Correlates With Negative Regulation of the c-myb Promoter Blood. 90: 1828-1839. DOI: 10.1182/Blood.V90.5.1828 |
0.432 |
|
| 1996 |
Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 93: 13137-42. PMID 8917557 DOI: 10.1073/Pnas.93.23.13137 |
0.433 |
|
| 1996 |
Perrotti D, Bellon T, Trotta R, Martinez R, Calabretta B. A cell proliferation-dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing element Blood. 88: 3336-3348. DOI: 10.1182/Blood.V88.9.3336.Bloodjournal8893336 |
0.442 |
|
| 1995 |
Piaggio G, Farina A, Perrotti D, Manni I, Fuschi P, Sacchi A, Gaetano C. Structure and growth-dependent regulation of the human cyclin B1 promoter. Experimental Cell Research. 216: 396-402. PMID 7843284 DOI: 10.1006/Excr.1995.1050 |
0.421 |
|
| 1995 |
Perrotti D, Melotti P, Skorski T, Casella I, Peschle C, Calabretta B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Molecular and Cellular Biology. 15: 6075-87. PMID 7565760 DOI: 10.1128/Mcb.15.11.6075 |
0.451 |
|
| Show low-probability matches. |